FIELD: biotechnology.
SUBSTANCE: present invention relates to genetically modified TCR-deficient T cells, and can be used in medicine to treat cancer. Method aims to produce a modified primary human T cell from a primary human T cell from a human donor that has been modified to reduce the expression of an endogenous T cell receptor (TCR). Method comprises introducing into the primary human T cell derived from a human donor at least one minigene having a nucleic acid sequence encoding a truncated CD3-zeta polypeptide and expressing said minigene to reduce the expression of the endogenous T cell receptor.
EFFECT: invention enables to reduce the graft-versus-host (GVHD) response in histocompatible human recipients compared to the GVHD response induced by the primary human T cell obtained from the same human donor, which has not been modified by the introduction of at least one minigene.
18 cl, 3 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| METHOD FOR CREATION OF T-CELLS SUITABLE FOR ALLOGENEIC TRANSPLANTATION | 2015 |
|
RU2752933C2 |
| IMPROVED IMMUNE CELLS WITH DOUBLE shRNA AND COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2793922C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| GENETICALLY MODIFIED GAMMA DELTA T CELLS | 2015 |
|
RU2756247C2 |
| IMMUNE CELLS DEFECTIVE BY Suv39h1 | 2018 |
|
RU2784531C2 |
| METHOD OF PRODUCTION OF T-CELLS | 2015 |
|
RU2813668C2 |
| REPRODUCTION AND USE OF NON-HEMATOPOIETIC TISSUE-RESIDENT γδ T-CELLS | 2016 |
|
RU2784566C2 |
| IMPROVED COMPOSITIONS BASED ON T-CELLS | 2015 |
|
RU2719030C2 |
| PRODUCTION OF CONSTRUCTED CELLS FOR ADOPTIVE CELL THERAPY | 2017 |
|
RU2780156C2 |
